GU
Fractyl Health, Inc.
GUTS · NASDAQ
$4.42 +4.49% (+$0.19)
1M -42.75%
Market Cap $55.9M
P/E Ratio -
Div. Yield -
ROE 1,625.88%
Bulios Fair Price
$3.44
22.2% downside
Current Price
$4.42
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GUTS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
-
N/A P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 128.88%
ROIC 120.27%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 3.15x
Net debt/EBITDA N/A
Debt/Equity N/A
Stability
28 /100
Unstable Profitable years 0
Beta 2.33x
EPS volatility 32.97%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GUTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Harith Rajagopalan
Employees
100
Headquarters
Burlington
Upcoming events
11 NOV
Earnings
Upcoming earnings report